A Case Control Study of the Prevalence of Pulmonary Hypertension in Patients With Myeloproliferative Diseases. (PH-MPD1)

Israel Healthcare Foundation

Status: Unknown

Conditions: Myeloproliferative Disease; Pulmonary Hypertension

Treatments: Other: myeloproliferative disease

Study type: Observational

Funder types: Other

Identifiers

NCT01884974

CMC-12-0060-CTIL

Details and patient eligibility

About

Pulmonary hypertension (PH) is defined as a group of diseases characterised by an elevated mean pulmonary artery pressure (Ppa) ≥25 mmHg at rest. Recently, chronic myeloproliferative diseases (CMPD) associated with pulmonary hypertension were included in the group 5 category, corresponding to PH for which the aetiology is unclear and/or multifactorial. CMPD include chronic myelogenous leukaemia, chronic neutrophilic leukaemia and chronic eosinophilic leukaemia (which primarily express a myeloid phenotype and polycythaemia vera), idiopathic myelofibrosis, and essential thrombocytosis in which erythroid or megakaryocytic hyperplasia predominates.

The purpose of this research:

1. Assess Prevalence of PH in patients with CMPD in Northern Israel
2. Describe the demographics and clinical course in patients with CMPD who are diagnosed with PH.

Full description

study will include the following:

• sex
• age
• BMI
• ethnicity
• age diagnosed with Myeloproliferative disease
• clinical manifestations of the myeloproliferative disease
• JAK2 mutation
• known hematological complications

Enrollment: 150 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. consenting patients diagnosed with a myeloproliferative disease

Exclusion criteria

1. Refusal to have an echocardiogram or answer the St. George respiratory questionnaire

Trial design

150 participants in 1 patient group

myeloproliferative disease

Description:

Patients with Myeloproliferative Diseases as specified under inclusion and exclusion criteria

Treatment:

Other: myeloproliferative disease